JBS N.V. (JBS) Stock Price & How to Invest

JBS processes and sells animal protein at a scale nobody else matches: beef, pork, chicken and lamb, slaughtered and packed in more than a dozen countries and shipped to roughly 180. The operating structure is really six businesses under one roof. JBS Beef North America is the largest by revenue (about $7.2 billion in the first quarter of 2026), followed by Pilgrim's Pride, the US chicken company JBS controls with a stake above 80% and which trades separately as PPC, then JBS Brazil, Seara (branded and prepared foods in Brazil, the highest-margin unit), JBS USA Pork and JBS Australia. Brands include Friboi, Swift, Seara, Moy Park, Primo and Pilgrim's. Revenue was about $86.2 billion in 2025 and roughly $88 billion over the trailing twelve months, which makes JBS one of the largest food companies on earth by sales and one of the smallest by market value relative to those sales, at around $15 billion.

The investment picture is a cattle-cycle story wrapped in a governance discount. In June 2025 the group completed a long-fought reorganization into a Dutch holding company, JBS N.V., and listed Class A shares on the NYSE while keeping Brazilian Depositary Receipts (JBSS32) on B3. The stated rationale was access to a deeper investor base and a valuation closer to US food peers. That re-rating has not arrived: shares traded near $13.70 in early August 2026, inside a 52-week range of $11.49 to $18.65, at roughly 8 times trailing earnings. The reason is visible in the segment numbers. The US cattle herd is at its smallest in about 75 years, cattle procurement costs are at records, and JBS Beef North America posted negative EBITDA of about $230 million on a -3.2% margin in the first quarter of 2026. Everything else worked: Seara ran a 15.5% EBITDA margin, US pork 13.5%, Pilgrim's Pride 9.9%, and group net income still came in at $221 million on $21.6 billion of revenue. The diversification is doing exactly what it is designed to do, which is why the group stays profitable through the worst beef environment in memory, and the market is deciding how much that is worth while the Batista family holds about 86% of the voting power.

This is a commodity processor, so margins are set by the spread between livestock costs and meat prices, and JBS controls neither. US beef is the acute problem: negative EBITDA in the first quarter of 2026 with no quick fix, since herd rebuilding tightens supply further before it loosens. Governance is the structural discount: Class B shares carry ten votes each and the controlling Batista family held about 85.7% of voting power as of March 2026, so minority Class A holders have effectively no say, and the family's history (the 2017 Brazilian leniency agreement and J&F's 2020 US guilty plea and $256 million penalty) still colors how some institutions view the name. The group also carries a long tail of antitrust and labor litigation across beef, pork and chicken, environmental and deforestation scrutiny including a New York Attorney General action over sustainability claims, and law-firm investigations tied to those disclosures. Trade policy is live: a 25% US tariff on many Brazilian goods took effect on July 22, 2026 with beef exempted, an exemption that could be revisited. Add currency translation across the real, dollar and Australian dollar, animal disease outbreaks that can close export markets overnight, and a Q2 2026 report due August 10 where consensus looks for roughly $0.32 of EPS, about 40% below the prior year.

14 analysts publish price targets on JBS, averaging $18.22 against a $13.69 price as of August 2026, or +33.1%. The published targets run from $14.91 to $20.29, a narrow spread, and the ratings split 13 buy, 2 hold, 0 sell. Over the last six months there have been 2 raises and 4 cuts among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.

Read the full JBS forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.

We give no verdict on JBS N.V.. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. Protein and geographic diversification as a built-in hedge. The 2026 numbers are the clearest demonstration of the model: US beef lost money while Seara, Brazilian beef, US pork and chicken carried the group to $1.13 billion of quarterly adjusted EBITDA and 22.1% return on equity. The most optimistic published target, $20.29, assumes this works close to its best case.

The case against. This is a commodity processor, so margins are set by the spread between livestock costs and meat prices, and JBS controls neither. The most pessimistic target, $14.91, is roughly what JBS is worth if this bites instead.

Read the full bull and bear case on JBS, including what would have to change to break either one. Walnut is not an investment adviser.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see JBS N.V.'s investor relations page or your broker.

• Revenue (TTM): ~$88 billion, after ~$86.2 billion in FY2025 (+11.7%)
• Q1 2026 results: ~$21.6 billion revenue (+11%), ~$1.13 billion adjusted EBITDA (5.2% margin), ~$221 million net income
• Net income / EPS (TTM): ~$1.74 billion, ~$1.62 per share
• Price / market cap: ~$13.70 a share, ~$15 billion, inside a 52-week range of ~$11.49 to ~$18.65
• Valuation multiples: ~8.4x trailing earnings, ~10x forward earnings, ~0.17x trailing sales
• Dividend and leverage: US$1.00 per share paid June 2026 (~7% on the current price), net debt ~2.77x EBITDA

JBS screens as one of the cheapest large food companies in the world on earnings and almost absurdly cheap on sales, but both readings need context. The trailing multiple sits on earnings that already absorb a loss-making US beef unit, so it is neither a peak nor a clean trough number, and the sub-0.2x sales ratio reflects packing economics where a 5% EBITDA margin is a normal outcome rather than a distressed one. Screens quoting a double-digit dividend yield are counting two US$1.00 distributions inside the trailing twelve months. As of early August 2026, roughly 15 covering analysts carried an average twelve-month target near $18, implying meaningful upside if the cattle cycle turns on schedule, and the Q2 2026 report on August 10 is the next test of that timing.

Other names that sit close to JBS: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. Worth a look if you are thinking about diversification within a thesis rather than concentration on one ticker.

There are three common ways to get JBS exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic portfolio, so JBS sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where JBS fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

JBS is a genuinely global protein business priced like a commodity processor stuck at the bottom of the US cattle cycle, with a controlling family, a large dividend and very little of the multiple that branded food peers earn.

Whether JBS is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is JBS a buy or a sell?, and where the stock could go from here in the JBS stock forecast.

For income investors, whether JBS pays a dividend and how the payout looks is covered in does JBS pay a dividend? And to weigh JBS against a peer, read the full side-by-side comparisons: JBS vs TSN and JBS vs CALM.